ES2555063T3 - Derivados de pirazolilaminopiridina útiles como inhibidores de quinasas - Google Patents
Derivados de pirazolilaminopiridina útiles como inhibidores de quinasas Download PDFInfo
- Publication number
- ES2555063T3 ES2555063T3 ES11167362.0T ES11167362T ES2555063T3 ES 2555063 T3 ES2555063 T3 ES 2555063T3 ES 11167362 T ES11167362 T ES 11167362T ES 2555063 T3 ES2555063 T3 ES 2555063T3
- Authority
- ES
- Spain
- Prior art keywords
- mmol
- alkyl
- pyrazol
- fluorophenyl
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65005305P | 2005-02-04 | 2005-02-04 | |
| US650053P | 2005-02-04 | ||
| US65332905P | 2005-02-16 | 2005-02-16 | |
| US653329P | 2005-02-16 | ||
| US72163305P | 2005-09-29 | 2005-09-29 | |
| US721633P | 2005-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2555063T3 true ES2555063T3 (es) | 2015-12-28 |
Family
ID=36177856
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11167362.0T Active ES2555063T3 (es) | 2005-02-04 | 2006-02-01 | Derivados de pirazolilaminopiridina útiles como inhibidores de quinasas |
| ES06701619T Active ES2375735T3 (es) | 2005-02-04 | 2006-02-01 | Derivados de pirazolilaminopiridina útiles como inhibidores de quinasas. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06701619T Active ES2375735T3 (es) | 2005-02-04 | 2006-02-01 | Derivados de pirazolilaminopiridina útiles como inhibidores de quinasas. |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8324252B2 (he) |
| EP (2) | EP1846394B1 (he) |
| JP (1) | JP5139084B2 (he) |
| KR (1) | KR101302945B1 (he) |
| CN (1) | CN101155800B (he) |
| AR (1) | AR056184A1 (he) |
| AT (1) | ATE530545T1 (he) |
| AU (1) | AU2006210710B2 (he) |
| BR (1) | BRPI0606793A8 (he) |
| CA (1) | CA2595834C (he) |
| CY (2) | CY1115078T1 (he) |
| DK (2) | DK2383268T3 (he) |
| ES (2) | ES2555063T3 (he) |
| HK (2) | HK1114374A1 (he) |
| HR (1) | HRP20110962T1 (he) |
| HU (1) | HUE025671T2 (he) |
| IL (1) | IL184674A (he) |
| ME (1) | ME02645B (he) |
| MX (1) | MX2007009437A (he) |
| MY (1) | MY149512A (he) |
| NO (1) | NO341112B1 (he) |
| NZ (1) | NZ561145A (he) |
| PL (2) | PL2383268T3 (he) |
| PT (2) | PT1846394E (he) |
| RS (1) | RS52061B (he) |
| SA (1) | SA06270007B1 (he) |
| SI (2) | SI2383268T1 (he) |
| TW (1) | TWI370127B (he) |
| UY (1) | UY29360A1 (he) |
| WO (1) | WO2006082392A1 (he) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0607455A2 (pt) | 2005-02-16 | 2009-09-01 | Astrazeneca Ab | composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica |
| EP1899323A2 (en) * | 2005-05-16 | 2008-03-19 | AstraZeneca AB | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
| PT1945631E (pt) | 2005-10-28 | 2012-10-15 | Astrazeneca Ab | Derivados de 4-(3-aminopirazole)pirimidina para utilização como inibidores da tirosina-cinase no tratamento do cancro |
| CA2666769A1 (en) * | 2006-10-18 | 2008-04-24 | Merck & Co., Inc. | 2-hydroxy-2-phenyl/thiophenyl propionamides as androgen receptor modulators |
| WO2008053812A1 (fr) * | 2006-10-27 | 2008-05-08 | Mitsubishi Tanabe Pharma Corporation | Dérivé de cyanopyridine et son utilisation médicale |
| TW200826937A (en) * | 2006-11-01 | 2008-07-01 | Astrazeneca Ab | New use |
| WO2008117050A1 (en) * | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
| UA99459C2 (en) * | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
| JP5524491B2 (ja) * | 2008-03-04 | 2014-06-18 | 石原産業株式会社 | ３−アミノ−２−クロロ−６−トリフルオロメチルピリジンの製造方法 |
| WO2010020810A1 (en) * | 2008-08-19 | 2010-02-25 | Astrazeneca Ab | 2-(imidaz0lylamin0)-pyridine derivatives and their use as jak kinase inhibitors |
| EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| NZ603837A (en) * | 2010-06-30 | 2014-01-31 | Fujifilm Corp | Novel nicotinamide derivative or salt thereof |
| UY33517A (es) | 2010-07-19 | 2012-02-29 | Astrazeneca Ab | Depósito farmacéutico para 5-fluoro-2-[[(1S)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1H-pirazol-3-il)amino]piridin-3-carbonitrilo?. |
| EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| KR101744607B1 (ko) * | 2011-12-28 | 2017-06-08 | 후지필름 가부시키가이샤 | 신규인 니코틴아미드 유도체 또는 그 염 |
| CN104334545A (zh) | 2012-03-16 | 2015-02-04 | 埃克希金医药品有限公司 | 3,5-二氨基吡唑激酶抑制剂 |
| TWI585088B (zh) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物 |
| EP2914585B1 (en) * | 2012-11-05 | 2018-03-07 | Emory University | 7,8-dihydroxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto |
| NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
| DK3179991T3 (da) | 2014-08-11 | 2021-12-06 | Acerta Pharma Bv | Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor |
| WO2016024228A1 (en) | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor |
| AR103264A1 (es) | 2014-12-23 | 2017-04-26 | Axikin Pharmaceuticals Inc | Derivados de 3,5-aminopirazol como inhibidores de quinasa rc |
| WO2017157885A1 (de) | 2016-03-16 | 2017-09-21 | Bayer Cropscience Aktiengesellschaft | N-(cyanbenzyl)-6-(cyclopropylcarbonylamino)-4-(phenyl)-pyridin-2-carboxamid-derivate und verwandte verbindungen als pestizide pflanzenschutzmittel |
| US20220235013A1 (en) | 2017-03-21 | 2022-07-28 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| US20220274979A1 (en) | 2018-04-18 | 2022-09-01 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| JP7318009B2 (ja) | 2019-05-21 | 2023-07-31 | 浙江海正薬業股▲ふん▼有限公司 | マクロライド誘導体、その製造方法および用途 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| ES2194181T3 (es) | 1996-02-13 | 2003-11-16 | Astrazeneca Ab | Derivados de quinazolina como inhibidores de vegf. |
| DK0885198T3 (da) | 1996-03-05 | 2002-03-25 | Astrazeneca Ab | 4-Anilinoquinazolinderivater |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| NZ506417A (en) | 1998-02-17 | 2003-05-30 | Tularik Inc | Anti-viral pyrimidine derivatives |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| DE19917785A1 (de) | 1999-04-20 | 2000-10-26 | Bayer Ag | 2,4-Diamino-pyrimidin-Derivate |
| US6399780B1 (en) | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
| MXPA02002559A (es) | 1999-09-10 | 2002-07-30 | Merck & Co Inc | Inhibidores de tirosina cinasa. |
| JP4794793B2 (ja) | 1999-12-28 | 2011-10-19 | ファーマコペイア， インコーポレイテッド | Ｎ−ヘテロ環ＴＮＦ−α発現阻害剤 |
| EP1257546A1 (en) | 2000-02-17 | 2002-11-20 | Amgen Inc. | Kinase inhibitors |
| EP1282607B1 (en) | 2000-05-08 | 2015-11-11 | Janssen Pharmaceutica NV | Prodrugs of hiv replication inhibiting pyrimidines |
| US7030123B2 (en) | 2000-05-31 | 2006-04-18 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| AU6623201A (en) | 2000-07-07 | 2002-02-05 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| JP2004502766A (ja) | 2000-07-07 | 2004-01-29 | アンギオジェン・ファーマシューティカルズ・リミテッド | 血管損傷剤としてのコルヒノール誘導体 |
| JP2004507526A (ja) | 2000-08-31 | 2004-03-11 | ファイザー・プロダクツ・インク | ピラゾール誘導体及びそのプロテインキナーゼ阻害剤としての使用 |
| EP1317446A1 (en) | 2000-09-01 | 2003-06-11 | Glaxo Group Limited | Oxindole derivatives |
| EP1339680A1 (en) | 2000-09-01 | 2003-09-03 | Glaxo Group Limited | Substituted oxindole derivatives as tyrosine kinase inhibitors |
| EP1317448B2 (en) | 2000-09-15 | 2011-05-04 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| DK1347971T3 (da) | 2000-12-21 | 2006-05-15 | Bristol Myers Squibb Co | Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien |
| JP4160395B2 (ja) | 2000-12-21 | 2008-10-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| WO2002064096A2 (en) | 2001-02-16 | 2002-08-22 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
| EP1430053B1 (en) | 2001-09-27 | 2006-10-25 | SmithKline Beecham Corporation | AZAOXOINDOLE DERIVATIVES AS Trk PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND CHRONIC PAIN |
| SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
| JP2003231687A (ja) | 2002-02-04 | 2003-08-19 | Japan Tobacco Inc | ピラゾリル縮合環化合物及びその医薬用途 |
| WO2004037814A1 (en) | 2002-10-25 | 2004-05-06 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| EP1656372B1 (en) | 2003-07-30 | 2013-04-10 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| MY141220A (en) * | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| WO2005103010A2 (en) | 2004-04-21 | 2005-11-03 | Astrazeneca Ab | Pyrazole derivatives useful for the treatment of cancer |
| CA2580838A1 (en) | 2004-09-27 | 2006-04-06 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| WO2006067614A2 (en) | 2004-12-23 | 2006-06-29 | Pfizer Products Inc. | Heteroaromatic derivatives useful as anticancer agents |
| US8211929B2 (en) | 2004-12-30 | 2012-07-03 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| DK1853602T3 (da) | 2005-02-16 | 2010-09-20 | Astrazeneca Ab | Kemiske forbindelser |
| BRPI0607455A2 (pt) * | 2005-02-16 | 2009-09-01 | Astrazeneca Ab | composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica |
| CN101208093A (zh) * | 2005-04-27 | 2008-06-25 | 阿斯利康(瑞典)有限公司 | 吡唑-嘧啶衍生物在治疗疼痛中的用途 |
| US7928126B2 (en) | 2005-04-28 | 2011-04-19 | Mitsubishi Tanabe Pharma Corporation | Cyanopyridine derivative and use thereof as medicine |
| US20080194606A1 (en) * | 2005-05-05 | 2008-08-14 | Astrazeneca | Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer |
| EP1899323A2 (en) * | 2005-05-16 | 2008-03-19 | AstraZeneca AB | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
| PT1945631E (pt) * | 2005-10-28 | 2012-10-15 | Astrazeneca Ab | Derivados de 4-(3-aminopirazole)pirimidina para utilização como inibidores da tirosina-cinase no tratamento do cancro |
| US7572809B2 (en) | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
| MX2008016523A (es) * | 2006-06-30 | 2009-01-19 | Astrazeneca Ab | Derivados de pirimidina utiles en el tratamiento de cancer. |
| TW200823196A (en) * | 2006-11-01 | 2008-06-01 | Astrazeneca Ab | New use |
| TW200826937A (en) * | 2006-11-01 | 2008-07-01 | Astrazeneca Ab | New use |
-
2006
- 2006-02-01 PT PT06701619T patent/PT1846394E/pt unknown
- 2006-02-01 RS RS20110563A patent/RS52061B/en unknown
- 2006-02-01 PL PL11167362T patent/PL2383268T3/pl unknown
- 2006-02-01 JP JP2007553688A patent/JP5139084B2/ja not_active Expired - Fee Related
- 2006-02-01 US US11/815,140 patent/US8324252B2/en not_active Expired - Fee Related
- 2006-02-01 EP EP06701619A patent/EP1846394B1/en active Active
- 2006-02-01 ES ES11167362.0T patent/ES2555063T3/es active Active
- 2006-02-01 WO PCT/GB2006/000334 patent/WO2006082392A1/en active Application Filing
- 2006-02-01 ME MEP-2011-563A patent/ME02645B/me unknown
- 2006-02-01 EP EP11167362.0A patent/EP2383268B1/en not_active Not-in-force
- 2006-02-01 CN CN2006800101082A patent/CN101155800B/zh not_active Expired - Fee Related
- 2006-02-01 DK DK11167362.0T patent/DK2383268T3/en active
- 2006-02-01 PT PT111673620T patent/PT2383268E/pt unknown
- 2006-02-01 DK DK06701619.6T patent/DK1846394T3/da active
- 2006-02-01 SI SI200631992T patent/SI2383268T1/sl unknown
- 2006-02-01 SI SI200631240T patent/SI1846394T1/sl unknown
- 2006-02-01 NZ NZ561145A patent/NZ561145A/en not_active IP Right Cessation
- 2006-02-01 CA CA2595834A patent/CA2595834C/en not_active Expired - Fee Related
- 2006-02-01 PL PL06701619T patent/PL1846394T3/pl unknown
- 2006-02-01 ES ES06701619T patent/ES2375735T3/es active Active
- 2006-02-01 HU HUE11167362A patent/HUE025671T2/en unknown
- 2006-02-01 AT AT06701619T patent/ATE530545T1/de active
- 2006-02-01 MX MX2007009437A patent/MX2007009437A/es active IP Right Grant
- 2006-02-01 BR BRPI0606793A patent/BRPI0606793A8/pt not_active IP Right Cessation
- 2006-02-01 KR KR1020077020258A patent/KR101302945B1/ko not_active IP Right Cessation
- 2006-02-01 AU AU2006210710A patent/AU2006210710B2/en not_active Ceased
- 2006-02-02 AR ARP060100376A patent/AR056184A1/es not_active Application Discontinuation
- 2006-02-03 UY UY29360A patent/UY29360A1/es not_active Application Discontinuation
- 2006-02-03 TW TW095103831A patent/TWI370127B/zh not_active IP Right Cessation
- 2006-02-03 MY MYPI20060475A patent/MY149512A/en unknown
- 2006-02-04 SA SA06270007A patent/SA06270007B1/ar unknown
-
2007
- 2007-07-17 IL IL184674A patent/IL184674A/he not_active IP Right Cessation
- 2007-07-20 NO NO20073791A patent/NO341112B1/no not_active IP Right Cessation
-
2008
- 2008-02-13 HK HK08101578.0A patent/HK1114374A1/xx not_active IP Right Cessation
-
2011
- 2011-12-21 HR HR20110962T patent/HRP20110962T1/hr unknown
-
2012
- 2012-01-11 CY CY20121100025T patent/CY1115078T1/el unknown
- 2012-05-02 HK HK12104298.7A patent/HK1163677A1/zh not_active IP Right Cessation
- 2012-11-29 US US13/688,790 patent/US8835465B2/en not_active Expired - Fee Related
-
2015
- 2015-11-26 CY CY20151101071T patent/CY1119077T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2555063T3 (es) | Derivados de pirazolilaminopiridina útiles como inhibidores de quinasas | |
| ES2308731T3 (es) | Compuestos quimicos. | |
| ES2347172T3 (es) | Compuestos quimicos. | |
| ES2328042T3 (es) | Derivados de pirazol como unhibidores de los receptores tirosina cinasa. | |
| ES2391783T3 (es) | Derivados de 4-(3-aminopirazol)pirimidina para su uso como agentes inhibidores de las tirosina cinasas en el tratamiento del cáncer | |
| BRPI0610184A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de cáncer e para a produção de um efeito anti-proliferativo em um animal de sanque quente, e, composição farmacêutica | |
| JP2008540391A (ja) | ピラゾリルアミノ置換ピリミジン、および癌の処置におけるそれらの使用 |